利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

162 条记录 (耗时 0.031 秒)

    Antibodies to programmed cell death protein 1
    65.
    发明授权
    Antibodies to programmed cell death protein 1 有权

    公开(公告)号：US11021540B2

    公开(公告)日：2021-06-01

    申请号：US16645289

    申请日：2018-09-07

    申请人： Augusta University Research Institute, Inc.

    发明人： Samir Khleif ,  Mikayel Mkrtichyan

    IPC分类号： A61K39/395 ,  C07K16/40 ,  C07K16/28 ,  A61P35/00 ,  A61K39/00

    摘要： Antibodies and antigen binding fragments thereof are provided that immunospecifically bind to PD-1, preferably human or mouse PD-1, and induce or promote an immune response that activates immune cell proliferation or activity. Contrary to the existing paradigm that PD-1 exclusively promotes a suppressive immune response, the disclosed antibodies and antigen binding fragments thereof, immunospecifically bind to PD-1 and cause an activating signal to be delivered to the immune cell that activates the immune cell rather than suppressing the immune cell. In one embodiment, the disclosed antibodies and antigen binding fragments thereof specifically bind to PD-1 expressed on immune cells. The binding of the disclosed antibodies and antigen binding fragments thereof to PD-1 on immune cells causes an activating signal to be transmitted into the immune cell, for example a signal that enhances or promotes cytokine production and/or activation of immune cell proliferation. Immune cells that express PD-1, include but are not limited to B and T cells as well as myeloid-derived cells. In one embodiment, the immune cell is a T cell, preferably a CD8+ T cell.

    Methods of Treating Sickle Cell Disease and Related Disorders Using Fumaric Acid Esters
    67.
    发明申请
    Methods of Treating Sickle Cell Disease and Related Disorders Using Fumaric Acid Esters 有权

    公开(公告)号：US20210113512A1

    公开(公告)日：2021-04-22

    申请号：US17031868

    申请日：2020-09-24

    申请人： Augusta University Research Institute, Inc.

    发明人： Vadivel Ganapathy ,  Pamela M. Martin

    IPC分类号： A61K31/225 ,  A61K31/17

    摘要： Methods of using one or more fumaric acid esters or pharmacologically active salts, derivatives, analogues, or prodrugs thereof to increase expression of fetal hemoglobin (HbF) are disclosed. The methods typically include administering to a subject an effective amount of one or more fumaric acid esters optionally in combination or alternation with hydroxyurea to induce HbF expression in the subject in an effective amount to reduce one or more symptoms of a sickle cell disorder, a hemoglobinopathy, or a beta-thalassemia, or to compensate for a genetic mutation is the human beta-globin gene (HBB) or an expression control sequence thereof. Pharmaceutical dosage units and dosage regimes for use in the disclosed methods are also provided.

    Antibodies to Programmed Cell Death Protein 1
    68.
    发明申请
    Antibodies to Programmed Cell Death Protein 1 有权

    公开(公告)号：US20210032341A1

    公开(公告)日：2021-02-04

    申请号：US16645289

    申请日：2018-09-07

    申请人： Augusta University Research Institute, Inc.

    发明人： Samir KHLEIF ,  Mikayel MKRTICHYAN

    IPC分类号： C07K16/28 ,  A61P35/00

    摘要： Antibodies and antigen binding fragments thereof are provided that immunospecifically bind to PD-1, preferably human or mouse PD-1, and induce or promote an immune response that activates immune cell proliferation or activity. Contrary to the existing paradigm that PD-1 exclusively promotes a suppressive immune response, the disclosed antibodies and antigen binding fragments thereof, immunospecifically bind to PD-1 and cause an activating signal to be delivered to the immune cell that activates the immune cell rather than suppressing the immune cell. In one embodiment, the disclosed antibodies and antigen binding fragments thereof specifically bind to PD-1 expressed on immune cells. The binding of the disclosed antibodies and antigen binding fragments thereof to PD-1 on immune cells causes an activating signal to be transmitted into the immune cell, for example a signal that enhances or promotes cytokine production and/or activation of immune cell proliferation. Immune cells that express PD-1, include but are not limited to B and T cells as well as myeloid-derived cells. In one embodiment, the immune cell is a T cell, preferably a CD8+ T cell.